Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.
Metsera has raised $215.0M in total funding. The most recent round was Series B. The last funding was announced in November 2024.
Metsera's investors include RA Capital Management, ARCH Venture Partners, Janus Henderson Investors, Wellington Management, Fidelity.
Metsera is headquartered in New York, United States.
Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.
Metsera is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Metsera — Funding & Investors." VCBacked, November 13, 2024, https://www.vcbacked.co/company/metsera. Accessed July 19, 2026.
VCBacked. (2024). Metsera — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/metsera
{{cite web |title=Metsera — Funding & Investors |url=https://www.vcbacked.co/company/metsera |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated